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Abstract: A retrospective case review study of viper envenomations collected by the 
Marseille’s Poison Centre between 1996 and 2008 was performed. Results: 174 cases were 
studied (52 grade 1 = G1, 90 G2 and 32 G3). G1 patients received symptomatic treatments 
(average hospital stay 0.96 day). One hundred and six (106) of the G2/G3 patients were 
treated with the antivenom Viperfav* (2.1+/-0.9 days in hospital), while 15 of them 
received symptomatic treatments only (plus one immediate death) (8.1+/-4 days in 
hospital, 2 of them died). The hospital stay was significantly reduced in the antivenom 
treated group (p < 0.001), and none of the 106 antivenom treated patients had immediate 
(anaphylaxis) or delayed (serum sickness) allergic reactions. Conclusion: Viperfav* 
antivenom was safe and effective for treating asp viper venom-induced toxicity.  
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1. Introduction 
 
Four species of vipers of the Vipera genus live in mainland France. Two of these species have not 
been implicated in causing serious envenomation [1]. Indeed the Basque viper (Vipera seoanei) and 
the meadow viper (Vipera ursini) are small snakes that live within a restricted area and are not 
medically significant [2]. The other two French viper species, i.e., the adder (Vipera berus) and the asp 
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viper (Vipera aspis) are larger snakes, ranging from 40 to 60  cm in length, and can cause life-
threatening envenomation. Since it is adapted to cold regions, Vipera berus can be found in 
Scandinavian countries beyond the Arctic polar circle. The northern half of France and the 
mountainous regions of central France mark the southernmost extension of the habitat of this species. 
This snake is common in Sweden and England. Vipera aspis, that requires sun and warm temperatures, 
is found mainly in the regions south of the Loire. It can proliferate in suitable environments. Pattern 
markings are highly variable, even within the same population. Our reporting of the data concerning 
Vipera aspis bites in Southeastern France over a 13-year period should provide clinicians with useful 
insights for the management of patients envenomed by native Vipera species, including those 
involving neurological toxicity. 
 
2. Composition of Venom and Circumstances Related to Envenomation 
 
The venoms of Vipera aspis and Vipera berus present similar compositions [1]. Both contain 
kininogenase (hypotensive bradykinin-releasing enzyme), prothrombin-activating factors, proteases, 
and hyaluronidases. Neurotoxins of the phospholipase A2 type have been found in the venom of some 
populations of Vipera aspis, but never in the venom of Vipera berus (Table 1) [3–12].  
The adder and asp viper are not aggressive. The most serious envenomations occur when the snake 
feels threatened: most severe poisonings happen when the victim either touches the snake unwittingly 
with his hand or attempts to handle it. Even neonate Vipera apis are capable of inflicting medically 
serious envenomations [1]. 
 
Table 1. Neurotoxic phospholipases A2 from European viper venom. 
Vipers  Neurotoxins  Activities  References 
Vipera aspis aspis, 
Nice city area 
ammodytoxin A, B, C 
vaspin 
Monomeric presynaptic 
Heterodimeric postsynaptic 
[3,4,21] 
[3,4,21] 
Vipera aspis zinnikeri, 
Montpellier city area 
PLA2-I  Heterodimeric postsynaptic  [5,6] 
Vipera ammodytes 
ammodytes 
ammodytoxin A, B, C 
vipoxin 
Monomeric presynaptic 
Heterodimeric postsynaptic 
[7] 
[8,9,10] 
Vipera ammodytes 
meridionalis 
vipoxin  Heterodimeric postsynaptic  [11,12] 
Vipera berus berus  None  None  [4] 
 
3. Clinical Features and Grading of Envenomation 
 
Since the beginning of the 1990s a French grading scale for viper envenomations (Table 2) has been 
validated [13,14], confirmed by several clinical series description [15,16] and is now used in other 
European countries [1]. Vipers inject venom under pressure and the bite lasts only a few tenths of a 
second. In some cases there may be only one puncture site. When there are two fang marks, the 
distance between them may initially be a few millimeters but then increase to over one centimeter as 
swelling develops. If pain is moderate and limited to the injection sites and if there is no progression of 
symptoms with time it can be safely concluded that no venom was injected (grade  0) [13,14]. Toxins 2009, 1 
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Envenomation from these snakes features immediate pain that can be severe. This pain is likely due to 
venom components such as proteases, biogenic amines and probably other constituents. Pain is 
followed within a few minutes by inflammatory edema and sometimes blistering at the bite site 
(grade 1). Most envenomations stabilize at grade 1 then regress spontaneously after 24 to 72 hours. In 
mainland France only 15 to 20% of envenomation progress to grade 2. This percentage is variable 
from one geographic location to another depending on the venomous species. Grade 2 symptoms can 
either occur rapidly (early grade 2) with the appearance of low blood pressure in the first 30 minutes 
after injection or be delayed (classic grade 2) for 6 to 16 hours with extensive swelling and sometimes 
general symptoms (vomiting, abdominal pain, malaise, and laboratory findings showing asymptomatic 
haemostatic disturbances). Two systemic signs are unfavorable prognostic indicators, i.e., diarrhea and 
arterial hypotension that does not resolve with fluid resuscitation or provision of colloids [1,15,16]. 
 
Table 2. Clinical gradation of European Viper envenomations [1,13,14]. 
Grade  Envenomation Clinical feature  Treatment 
Average 
venom blood 
level [13,14] 
0  Dry bite  Fang marks, no local signs  Local wound 
care only 
1 ± 0.3 ng/mL 
1  Minor  Local swelling, pain, no general 
symptoms 
Symptomatic  5 ± 1.8 ng/mL 
2  Moderate  Extensive swelling and/or moderate 
general symptoms (hypotension, 
moderate digestive troubles) 
Antivenom  32 ± 7 ng/mL 
3  Severe  Giant swelling and severe general 
symptoms (progression of grade 2 
symptoms, diarrhoea) 
Antivenom  126 ± 50 ng/mL 
 
Grade 3 envenomations are defined as grade 2 symptoms that continue to progress for several hours 
without specific treatment with development of extensive swelling at the trunk. General symptoms 
persist at grade  3 with numerous complications that can lead to multiple organ failure (renal 
insufficiency due to tubulopathy or glomerular nephropathy, hypoxia with variable bleeding due to 
pulmonary lesions related to edema and sometimes with pleural effusion, multiple episodes of 
digestive or respiratory bleeding, etc.). Laboratory tests may detect abnormalities as early as grade 2 
including thrombocytopenia, hyperleukocytosis, and hypofibrinogemia, but severe water-electrolyte 
imbalance or coagulation disturbances are associated with grade 3. 
Studies carried out on blood samples from viper bite victims show that the severity of 
envenomation is closely linked to the concentration of venom in the blood. Using ELISA to measure 
venom blood level can predict short-term clinical course (Table 2) [13,14,17]. However this technique 
is still experimental and is not yet applicable in emergency situations [1]. 
Neurotoxins in the venom of some asp vipers can cause special clinical manifestations with a 
decrease in local or regional symptoms (although still present after injection of venom) and appearance 
of general neurologic signs within 4 to 12 hours [18,19]. The most frequent symptom is ptosis but 
other signs have been reported including ophthalmoplegia, diplopia, dysarthria, paralysis of the Toxins 2009, 1 
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orbicularis oris and difficulty in swallowing and focusing (Table  3). More extensive neurological 
manifestations may be observed with drowsiness, vertigo, dyspnea, and diffuse paresthesia [20]. As 
shown in Figure 1A, this unusual envenomation pattern has been described only in small zones in 
southern France [20,21]. The grading system used for typical envenomation (Table  2) is also 
applicable to viper envenomations involving neurotoxins. In this regard, neurologic manifestations 
should be considered as general signs and are associated with grade 2 classification [1]. 
 
Table 3. Clinical feature of 14 neurotoxic viper envenomations observed in the Marseille’s 
Poison Centre during the 1996–2008 present study. French department codes:   
12 = Aveyron, 34 = Hérault, 06 = Alpes Maritimes and 04 = Alpes de Haute Provence. 
French department code  12  34  06  04  Total 
Subspecies  Vipera aspis zinnikeri 
Montpellier city area 
Vipera aspis aspis 
Nice city area 
2 
subspecies 
n  3  1  5  5  14 
M/F  2/1  1/0  3/2  4/1  10/4 
Age in years min.-max.  4–62  5  32–68  36–88  4–88 
Grade 1/2/3  0/3/0  0/1/0  0/4/1  0 /3/2  0/11/3 
Local signs 
      Local swelling 
      Extensive swelling 
 
2 
1 
 
1 
0 
 
1 
4 
 
2 
3 
 
6 (43%) 
8 (57%) 
Neurological symptoms 
Ptosis 
Ophtalmoplegia 
Vision troubles 
Dysphagia 
Dysphonia 
Paresthesias 
Drowsiness 
Lips paralysis  
Muscle weakness 
 
3 
2 
1 
1 
1 
1 
2 
2 
1 
 
1 
1 
0 
1 
1 
0 
1 
0 
0 
 
5 
3 
2 
3 
4 
3 
1 
1 
0 
 
5 
3 
3 
1 
0 
1 
0 
0 
0 
 
14 (100%) 
9 (64%) 
6 (43%) 
6 (43%) 
6 (43%) 
5 (25%) 
4 (29%) 
3 (21%) 
1 (7%) 
Other general symptoms  3  0  5  5  13 (93%) 
Antivenom treated 
patients 
2  1  5  5  13 (100%) 
 
4. Treatment Protocol Used for Viper Envenomation in Mainland France 
 
Management of viper envenomation must follow strict rules both at the scene of the snake bite and 
during transportation to the hospital [1,15]. 
First aid at the scene immediately after the bite: Immobilize the victim since any type of activity 
can increase spreading of the venom. Call for assistance as soon as possible. If the bite takes place in a 
remote area and it is necessary to seek a means of communication, the victim can be carried (e.g., 
children) but also left at the scene (preferably in the company of another person). The exact location of 
the bite scene must be specified. While waiting for assistance to arrive, remove tight clothing and Toxins 2009, 1 
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jewelry (watches, bracelets, etc.) from the bitten extremity to avoid tightening due to swelling and, if 
possible, disinfect the wound. 
What not to do: Do not restrict circulation by applying a tight band or tourniquet. Do not promote 
spreading by administering drinks that increase heart rate (coffee or tea), performing mutilating acts 
such as wound incisions, suctioning, or cauterization. Alcoholic beverages and recreational drugs must 
be prohibited for bitten patients. Antivenom should not be administered without medical supervision.  
What is not useful: Immediate use of heparin or its derivatives is unnecessary. Injection of low-
molecular weight heparin may promote spreading of venom. Similarly administration of 
corticosteroids is not useful. Aspiration devices like pumps cannot extract venom deeply injected in 
the victim’s tissues. 
Management during transportation to the hospital: The presence of any local manifestations 
indicates grade 1 envenomation and requires hospitalization. Placement of an intravenous line is a 
necessary precaution to allow immediate vascular filling by macromolecules in case of arterial 
hypotension. Non-sedating analgesics should be administered to patients in case of severe pain. 
Management at the hospital: Prompt clinical assessment (examination and interview) is necessary to 
establish envenomation grade upon arrival at the hospital (Table 2) [13,14]. Thorough laboratory 
testing should be carried out including hemogram, hemostasis (platelets, prothrombin rate, INR, 
fibrinogen, and detection of fibrin degradation products), and kidney functional testing (creatinemia, 
hematuria, and proteinuria). 
If the patient presents grade 0 envenomation, a 4-hour observation period in the emergency room 
may be proposed. However the need for such surveillance is controversial since absence of pain 
signifies that no venom has been injected and thus all but rules out the risk of progression from grade 0 
to grade 1.  
If the patient presents grade  1 envenomation symptoms, hospitalization is required for at least 
24  hours since venom has been injected and it is impossible to predict the outcome. Appropriate 
supportive treatment should be administered: analgesics, raising and immobilizing the extremity. As 
infectious complications are rare in Europe antibiotics should be administered only if infection is 
suspected. In this regard purulent material coming from the site of venom injection is a common early 
indicator of bacterial growth [1]. 
If the patient presents grade 2 or 3 envenomation, it is necessary to undertake the only specific 
treatment with proven effectiveness, i.e., intravenous immunotherapy with antivenom. The only 
antivenom currently available in France is Viperfav* that contains F(ab’)2 fragments obtained from 
antibodies produced by immunizing horses with venom collected from Vipera berus, Vipera aspis and 
Vipera ammodytes of the Balkan area (500LD50, 1000LD50, and 1000LD50 respectively per 4 mL 
bottle). Viperfav* has been approved for marketing and use only in a hospital setting. Although it 
appears to be well tolerated (no reports of severe adverse effects), Viperfav* contains heterologuous 
proteins that require use under surveillance at a medical facility. Approval of Viperfav* was obtained 
based on studies showing good tolerance and excellent effectiveness as an antidote in envenomated 
patients [15,16]. Quantities of required antivenom depends not on the victim but rather on the clinical 
feature and on the quantity and quality of the venom injected that vary depending on the age and health 
of the snake as well as on the circumstances in which the bite occurs. The pediatric dosage of 
antivenom is the same as in adults and only the volume of saline used to dilute the antivenom changes. Toxins 2009, 1 
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Prompt use of antivenom is recommended for pregnant women in order to neutralize circulating 
venom that may be toxic for the placenta and fetus [1,15]. It must be emphasized that immunotherapy 
is the only technique with proven efficacy against grade 2 or 3 envenomation. Preventing the life-
threatening effects of envenomation takes priority over the risk of anaphylactic reaction that is 
manageable most of time in a properly-equipped hospital setting. 
Thanks to techniques now available for purification of antivenoms including Viperfav* as well as to 
current levels of viral security, the intravenous injection route is recommended for immunotherapy. 
Use of the intramuscular route has been discontinued. In this regard toxicokinetic studies have shown 
that the intravenous route provides prompt neutralization of antigens not only in the bloodstream but 
also in tissue [22–25].  
The phospholipase A2 neurotoxins present in the venom of some asp vipers in France are similar to 
the neurotoxins (vipoxin and ammodytoxins) found in Vipera ammodytes (Table 1) [3–12]. Venom 
from Vipera ammodytes is used to immunize horses for production of Viperfav*. Antibodies against 
neurotoxins from Vipera ammodytes have been effective in improving the neurotoxic manifestations 
observed after snakebites in some areas of France. For this reason use of Viperfav* is recommended 
for neurotoxic envenomations with no change in dosage: clinical experience showed that one 
Viperfav* infusion is sufficient to induce a rapid decrease of the neurological symptoms [26]. 
Infection after snakebite regardless of clinical envenomation grade is a slight but non-negligible 
risk. However there is no consensus on the need for systematic antibacterial therapy [1,15]. Although 
the mouth of these serpents is highly septic, infection is uncommon. It is important to monitor the 
wound site so that treatment can be started at the first sign of infection [1]. Tetanus has never been 
observed following snakebite in Europe but this type of accident provides an opportunity to check and, 
if necessary, update tetanus immunization status. 
Anticoagulant treatment using heparin or low-molecular weight derivatives has no interest for the 
management of the direct venom induced toxicity. This treatment is necessary in only two cases. The 
first indication is to prevent possible venous thrombosis in patients presenting snakebites located on 
the lower extremity with extensive edema requiring prolonged decubitus. The second indication for 
anticoagulant treatment involves patients presenting grade  3 envenomation with disseminated 
intravascular syndrome [1,13]. 
The role of surgery is limited and currently subject to controversy. In the past fasciotomy was 
recommended in cases involving extensive edema in order to relieve pressure and avoid peripheral 
ischemia due to compression. Current experience has demonstrated that immunotherapy using 
antivenom leads to prompt reduction in edema thus ruling out the risk of compression. Peripheral 
ischemia was not observed in any patient included in recent series of snakebites attributed to European 
vipers with or without antivenom immunotherapy. Thus fasciotomy is generally considered as 
unnecessary for viper envenomation in Europe and used only in rare cases for snakebites by other 
species (genus Crotalus) [1]. 
 
5. Data Collection 
 
The Poison Control Center of the Marseille Public Hospital System is a clinical toxicologic 
department providing 24/7 emergency telephone assistance. The Center serves three regions in Toxins 2009, 1 
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mainland France, i.e., Provence-Côte d’Azur, Languedoc-Roussillon and Corsica, covering the whole 
French Mediterranean coastline. There are no venomous vipers in Corsica (Figure 1A). As part of a 
study to evaluate the therapeutic protocol currently used to treat viper envenomation in France, activity 
at the Marseille Poison Control Center has been closely monitored since 1996, which corresponds to 
the date when Viperfav* antivenom became available to Poison Control Centers (availability to all 
French hospitals since 2000). Data concerning all cases of snakebite recorded in mainland France were 
collected based on collaboration between the Poison Control Center and the hospital department where 
patients were treated. The presented case series is limited to the clinical experience of one French 
Poison Centre and is not linked to a clinical trial (descriptive clinical experience study with no 
randomized populations or blinded analysis). All clinical and laboratory findings were recorded in a 
computer database developed specifically for the purpose using Microsoft Access*. Retrospective 
analysis was performed on data for all cases involving grade  1 envenomation or higher recorded 
between the beginning of 1996 and end of 2008. Statistical calculation (patients characteristics, 
performed treatments, evolution of the envenomation, duration of hospitization…) was performed 
using the SPSS* software package. 
 
Figure 1. Asp Viper envenomation, experience of the Marseille Poison Centre between 
1996 and 2008. In A, the geographical distribution of dangerous vipers in mainland France 
is coloured in grey. The two black areas indicate the places where neurotoxic symptoms 
are observed. Both of them are included in the Marseille poison centre activity zone (all the 
French Mediterranean coast, at the south of the dotted line). The chronological distribution 
of the asp viper envenomation of the case series is presented by year in B and by month in 
C. In D, annual distribution of grade 2 + 3 envenomations with or without antivenom 
treatment. 
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Figure 1. Cont. 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Results 
 
During the 13-year study period, a total of 174 viper envenomations classified as grade 1 or higher 
were recorded at the Marseille Poison Control Center (Table 4). There were 120 men and 54 women 
with a mean age of 34 years (range, 2 to 88 years). Breakdown of data according to annual (Figure 1B) 
and seasonal (Figure 1C) showed an unequal chronological distribution of envenomations. Bites 
almost always occurred in the summertime but a few occurred in the middle of winter (Figure 1C). 
Analysis of the circumstances surrounding winter envenomations showed that most were inflicted by 
snakes that were disturbed during hibernation by victims who often reported having placed their hands 
in a wood stack or in a whole in an old wall. 
 
Table 4. Description of the 174 cases of viper envenomations managed by the Marseille 
Poison Centre between 1996 and 2008 inclusive. 
Grade  n 
Child/ 
adult * 
Neurotoxic 
symptoms 
Place of medical management 
Patients 
treated 
with anti-
venom  
Evolution 
 
Home  Emerg.  Spe. U  ICU 
Rapid 
recovery 
Delayed 
recovery 
Death 
1  52  12/40  0  8%  92%  0  0  0  96%   4%  0 
2  90  28/62  11 (12%)  0  77%  13%  10%  80 (89%)  89%  11%  0 
3  32  8/24  3 (9%)  3% **  0  3%  94%  26 (81%)  72%  19%  9% 
Total  174  48/126  14 (8%)  3%  67%  6%  24%  106 (61%)  88%  10%  2% 
* There is no significant difference in the grade distribution between adults and child patients with 
a Chi2 statistical test. 
** One patient died in few minutes after the bite by direct intravascular venom injection, and 
before any medical management. 
Emerg. = Emergency room, Spe. U = Specialized Unit, ICU = Intensive Care Unit. 
 Toxins 2009, 1 
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Data breakdown according to severity showed that 52 patients remained at grade 1. Most of these 
patients (92%) were examined in hospital emergency rooms. They remained a day at the hospital for 
observation to rule out progression to grade  2 and were released if no change was observed. 
Appropriate supportive treatment was administered to enhance comfort but antivenom immunotherapy 
was never used in compliance with the therapeutic protocol. In two cases recovery was delayed due to 
infectious complications, thus underlining the fact that the toxic and infectious risks are completely 
unrelated. Patients should be advised of the risk of infection even if envenomation is minimal. 
Grade 2 envenomations were most common (n = 90). All grade 2 patients were hospitalized for 
observation in the emergency room (77%), in specialized units, e.g. pediatric or traumatology 
departments (13%), or directly in intensive care units if the patient displayed additional risk factors 
(10%). Although the therapeutic protocol current used in France calls for immunotherapy for grade 2 
patients, antivenom was used in only 80 of the 90 cases (Table 4, Figure 1D). It is noteworthy that all 
patients who received the antidote treatment recovered rapidly with a mean hospitalization period of 
less than 2 days. In contrast delayed recovery (more than 3 days) was observed in all grade 2 patients 
who did not receive immunotherapy with a mean hospitalization period of about one week. The 
difference in mean hospitalization period between grade  2 patients who did and did not receive 
antivenom immunotherapy was highly significant (Table 5).  
 
Table 5. Duration of envenomed patient hospitalization with or without antivenom treatment. 
Grade  
Average hospitalization duration (days)  Total (days) 
Without/With antivenom  No antivenom  1 infusion  2 infusions  3 infusions or more 
1  0.96 ± 0.8  NA  NA  NA  0.96 ± 0.8/NA 
2  6.8 ± 3.6  1.9 ± 0.85  2.3 ± 0.6  1.75 ± 0.5  6.8 ± 3.6/1.9 ± 0.8 (p = 0.002) 
3  10.6 ± 4 *  3 ± 0.8  2.4 ± 0.9  2.7 ± 1  10.6 ± 4 */2.6 ± 0.9 (p < 0.02) 
2 + 3  8.1 ± 4 *  1.95 ± 0.9  2.3 ± 0.7  2.4 ± 0.95  8.1 ± 4 * /2.1 ± 0.9 (p < 0.001) 
*  The case of immediate death is not included in the calculation of the average hospitalization 
duration; NA = Not Applicable. 
 
Grade 3 envenomation was less common, with only 32 cases in this series. Patients presenting 
severe symptoms often associated with clinical and laboratory complications were usually admitted to 
the intensive care unit. An unusual case of snakebite with direct intravascular injection of venom led to 
death within a few minutes with no time for management (man, 45 years old, without previous medical 
history, bitten in the thigh in July 2004). Autopsy demonstrated massive myocardial injury with 
minimal local manifestations. Since the victim was classified as a home-treatment case in violation of 
the standard protocol for grade 3 envenomation (Table 4), this case was not taken into account for 
calculation of mean hospital stay. Most of the other grade 3 envenomations involved patients in whom 
management was delayed or in whom grade 2 was allowed to progress to grade 3 due to failure to 
provide antivenom in time. Five of the grade 3 patients that were managed in the hospital did not 
undergo immunotherapy including two that died despite intensive care management (women, 69 years 
old, without previous medical history, bitten in June 1996 on the foot and died after 4 days in ICU due 
to hemorrhagic and pulmonary complications; women, 45 years old, without previous history, bitten in 
June 2005 on the foot and died after 4 days in ICU due to cardiac and pulmonary complications) and Toxins 2009, 1 
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three in whom recovery was delayed. The mean duration of hospitalization in patients who were not 
treated with specific antivenom therapy was 10.6 days. This duration that is probably negatively 
skewed by the short stays of the 2 patients who died is still significantly higher than the 3-day mean 
observed for patients who were treated with antivenom. This finding demonstrates that immunotherapy 
is useful even for patients in whom management has been delayed or in whom tissue complications 
have already developed. 
Breakdown of envenomation severity according to patient age showed no difference in grade 
distribution between adults and children less than 15  years (age considered as the best cutoff to 
distinguish lower body weight and less resistant young cases from standard adult cases). This finding 
indicates that there is no need to modify the therapeutic protocol for children [1].  
Multiple Viperfav* perfusions did not reduce the duration of hospitalization of grade  2 and  3 
patients (Table 5). In this regard it should be underlined that the initial protocol calling for repeating 
antivenom infusions every 4 hours until observation of clinical improvement was proposed before 
marketing of Viperfav* began. Evidence based on subsequent clinical experience of French Poison 
Centres has shown that a single dose of antivenom contains sufficient antibodies to rule out the need 
for repeated infusion : unpublished data from the Angers Poison Control Center (Workshop on 
envenomation by vipers in Europe and their treatment with antivenoms, National Museum of Natural 
History in Paris, November 10, 2006) showed that venom levels in the blood of patients treated with 
Viperfav* decrease after the first round of antivenom and never increase thereafter. Our results are in 
agreement with this finding and thus indicate that multiple infusions are unwarranted. Regarding 
tolerance to Viperfav*, it is important to note that no immediate (anaphylactic reaction) or delayed 
(serum sickness) adverse effect was recorded during prolonged follow-up of the 106 patients (Table 4) 
who underwent a total of 162 Viperfav* infusions. 
In two circumscribed locations in France envenomation was characterized by neurotoxic 
manifestations (Figure 1A). In this series a total of 14 patients bitten in these areas presented clinical 
manifestations different from those observed elsewhere (Table  3). Recent studies show that the 
neurotoxins in the two populations belonging to different subspecies are different (Tables 1 and 3, 
Figure 2) [20,21,27].  
 
Figure 2. The snake with the typical morphology of Vipera aspis aspis and responsible for 
one of the first neurotoxic envenomation observed in 1992 near the city of Nice (Italian 
border). 
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In our series all patients who presented neurotoxic manifestations responded rapidly to 
immunotherapy using Viperfav* and recovered within two  days. These results confirm that this 
antivenom containing antibodies against neurotoxins from Vipera ammodytes is effective in 
neutralizing neurotoxins from both populations of « neurotoxic » asp vipers [26]. It is also noteworthy 
that another supposed neurotoxic snake species lives in the southern France, i.e., the Montpellier snake 
(Malpolon monspessulanus), and that its habitat covers both regions in which the neurotoxic vipers are 
found in France. However it is unlikely that confusion of two species occurred since the Montpellier 
snake is larger and more aggressive than the asp viper. In addition rare descriptions of envenomations 
by  Malpolon are characterized by slight or minimal local signs even if neurotoxicity is observed 
immediately [28]. This pattern was never observed after asp viper envenomation in our series. 
 
7. Discussion 
 
The asp viper is rightly considered as the most dangerous venomous snake in mainland France. 
Despite its relatively small size and fairly non- aggressive behavior, this species has been implicated in 
numerous grade 2 and 3 envenomations. It is important to note that the antivenom now available in 
France is a well-purified product that is safer than most other antivenoms (no adverse effect observed 
in our series or registered by the French pharmacovigilance system). The argument that the cost of this 
product is prohibitive (about 1,000 euros per infusion) is untenable in the light of published data 
[15,16] and the results of our series showing that use of antivenom significantly decreases the length of 
hospitalization by several days. Thus the product cost is offset by savings on other health care 
expenses. Although there is no reason for not using this antidote for grade 2 and 3 envenomation, some 
clinicians are still reluctant (Figure 1D) due to past experience with earlier poorly purified antivenoms 
that are no longer available in France. At the present time failure to administer a dose of Viperfav* to 
grade 2 or 3 patients should be considered as a serious treatment error.  
Analysis of medical records for this study also revealed that many treatment teams expressed an 
opposite concern by asking why antivenom immunotherapy was not indicated for grade  1 
envenomation. Indeed our data describing follow-up in the days after release from the hospital was that 
all patients who underwent prompt immunotherapy using Viperfav* for grade 2 envenomation were 
fully recovered upon returning home whereas most grade  1 patients presented persistent minor 
symptoms, i.e., edema, pain (sometimes causing disability) and functional disturbances, for several 
days despite appropriate symptomatic treatment. Despite this discrepancy, French authorities maintain 
the position that improvement in patient comfort does not warrant the use of costly heterologous 
proteins with a potential allergic risk [15,16]. 
This study also confirms the presence of viper populations with neurotoxic venom in southern 
France as initially reported in the early 1990s [18,19,21]. This finding underscores the evolving nature 
of venoms. Venoms are subject to multiple environmental factors and thus to constant evolutionary 
pressure. This fact must be taken into account by medical practitioners that must be able to adapt 
management protocols quickly and to admit that accepted clinical and therapeutic standards can 
become obsolete. With regard to neurotoxic venom it should be noted that neurotoxic asp vipers have 
also been observed in Italy [29].  
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